Ausgabe 1/2010
Inhalt (37 Artikel)
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
A. Valachis, N. P. Polyzos, N. Α. Patsopoulos, V. Georgoulias, D. Mavroudis, D. Mauri
Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint
Nicholas J. Robert
Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis
Eun-Ha Lee, Sue K. Park, Boyoung Park, Sung-Won Kim, Min Hyuk Lee, Sei Hyun Ahn, Byung Ho Son, Keun-Young Yoo, Daehee Kang
Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Tobias M. Weissenbacher, Madeleine Zschage, Wolfgang Janni, Udo Jeschke, Thomas Dimpfl, Doris Mayr, Brigitte Rack, Christian Schindlbeck, Klaus Friese, Darius Dian
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt, Alvin T. Lo, Catherine C. Park, Joe W. Gray, Mina J. Bissell
PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
Mohammed A. Aleskandarany, Emad A. Rakha, Mohamed A. H. Ahmed, Desmond G. Powe, Emma C. Paish, R. Douglas Macmillan, Ian O. Ellis, Andrew R. Green
The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines
Lauren A. Licata, Christine L. Hostetter, James Crismale, Anjali Sheth, Judith Clancy Keen
Evidence for a transcriptional signature of breast cancer
Yumei Feng, Xiaoqing Li, Baocun Sun, Yuli Wang, Lina Zhang, Xiuhua Pan, Xiaohui Chen, Xiaoyan Wang, Jinfeng Wang, Xishan Hao
In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up
P. Bult, P. Manders, H. M. P. M. Straatman, V. C. G. Tjan-Heijnen, L. V. A. M. Beex, J. Hendriks, J. W. Leer, A. L. M. Verbeek, R. Holland
A dose- and time-controllable syngeneic animal model of breast cancer microcalcification
Fangbing Liu, Preeti Misra, Elaine P. Lunsford, Joanne T. Vannah, Yuxia Liu, Robert E. Lenkinski, John V. Frangioni
Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients
Li-Chen Tang, Wen-Jin Yin, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao
The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer
Emmet McIntyre, Edith Blackburn, Philip J. Brown, Colin G. Johnson, William J. Gullick
Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation
Martín A. Rivas, Mercedes Tkach, Wendy Beguelin, Cecilia J. Proietti, Cinthia Rosemblit, Eduardo H. Charreau, Patricia V. Elizalde, Roxana Schillaci
Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations
Antoinette Hollestelle, Fons Elstrodt, Mieke Timmermans, Anieta M. Sieuwerts, Jan G. M. Klijn, John A. Foekens, Michael A. den Bakker, Mieke Schutte
Adoptively transferred ex vivo expanded γδ-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer
Benjamin H. Beck, Hyung-Gyoon Kim, Hyunki Kim, Sharon Samuel, Zhiyong Liu, Robin Shrestha, Hilary Haines, Kurt Zinn, Richard D. Lopez
Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor α and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts
Céline Bouclier, Véronique Marsaud, Olivia Bawa, Valérie Nicolas, Laurence Moine, Paule Opolon, Jack-Michel Renoir
Induction of the small heat shock protein αB-crystallin by genotoxic stress is mediated by p53 and p73
Joseph R. Evans, Joshua D. Bosman, Lauren Brown-Endres, Fruma Yehiely, Vincent L. Cryns
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
Emilio Alba, Manuel Ruiz-Borrego, Mireia Margelí, Álvaro Rodríguez-Lescure, Pedro Sánchez-Rovira, Amparo Ruiz, Jose Ramón Mel-Lorenzo, Manuel Ramos-Vázquez, Nuria Ribelles, Elisa Calvo, Antonio Casado, Antonia Márquez, David Vicente, José Angel García-Sáenz, Miguel Martín
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer
C. G. Murphy, M. Khasraw, A. D. Seidman
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
Valentina Guarneri, David Miles, Nicholas Robert, Véronique Diéras, John Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, PierFranco Conte
SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls
Zhanwei Wang, Yuanyuan Fu, Chunbo Tang, Su Lu, Wen-ming Chu
Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk
Grete S. Pedersen, Janneke G. F. Hogervorst, Leo J. Schouten, Erik J. M. Konings, R. Alexandra Goldbohm, Piet A. van den Brandt
Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer
Edoardo Botteri, Maria Teresa Sandri, Vincenzo Bagnardi, Elisabetta Munzone, Laura Zorzino, Nicole Rotmensz, Chiara Casadio, Maria Cristina Cassatella, Angela Esposito, Giuseppe Curigliano, Michela Salvatici, Elena Verri, Laura Adamoli, Aron Goldhirsch, Franco Nolè
Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point”
T. Fehm, W. Sauerbrei
No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects
Lei Yao, Fang Fang, Qi Wu, Zhen Yang, Yang Zhong, Long Yu
Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study
Susan E. McCann, Lilian U. Thompson, Jing Nie, Joan Dorn, Maurizio Trevisan, Peter G. Shields, Christine B. Ambrosone, Stephen B. Edge, Hsin-Fang Li, Christina Kasprzak, Jo L. Freudenheim
No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects
Lei Yao, Fang Fang, Qi Wu, Yang Zhong, Long Yu
The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger
Chan H. Han, Jiachun Lu, Qingyi Wei, Melissa L. Bondy, Abenaa M. Brewster, Tse-Kuan Yu, Thomas A. Buchholz, Banu K. Arun, Li-E Wang
Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis
Ke-Da Yu, Ao-Xiang Chen, Chen Yang, Li-Xin Qiu, Lei Fan, Wen-Huan Xu, Zhi-Ming Shao
Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls
Chen Mao, Xi-Wen Wang, Ben-Fu He, Li-Xin Qiu, Ru-Yan Liao, Rong-Cheng Luo, Qing Chen
TNFα −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls
Fang Fang, Lei Yao, Xiao Jia Yu, Lu Yu, Qi Wu, Long Yu
Transforming growth factor-β1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case–control studies
Xiaowei Qi, Fan Zhang, Xinhua Yang, Linjun Fan, Yi Zhang, Li Chen, Yan Zhou, Xianchun Chen, Ling Zhong, Jun Jiang
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
Amanda B. Spurdle, Paul Fahey, Xiaoqing Chen, Lesley McGuffog, Douglas Easton, Susan Peock, Margaret Cook, Jacques Simard, Tim R. Rebbeck, Antonis C. Antoniou, Georgia Chenevix-Trench
High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays
Christopher Schroeder, Fanny Stutzmann, Bernhard H. F. Weber, Olaf Riess, Michael Bonin
PALB2 mutations in male breast cancer: a population-based study in Central Italy
Valentina Silvestri, Piera Rizzolo, Ines Zanna, Mario Falchetti, Giovanna Masala, Simonetta Bianchi, Laura Papi, Giuseppe Giannini, Domenico Palli, Laura Ottini
PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations
Jin Ho Kim, Doo Ho Choi, Dae Yeon Cho, Sei Hyun Ahn, Byung Ho Son, Bruce G. Haffty